Growth Hormone Deficiency - Pipeline Review, H1 2014: 24 Companies and 23 Drugs Profiled
M2 - Thu May 08, 3:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdp2w7/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - Access Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Ascendis Pharma A/S - Biogenomics - Bolder Biotechnology, Inc. - Braasch Biotech LLC - CJ CheilJedang Corp. - Critical Pharmaceuticals Limited - Delpor, Inc. - Emisphere Technologies, Inc. - Flamel Technologies S.A. - HanAll Biopharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - LG Life Sciences, Ltd. - OPKO Health, Inc. - Pfenex Inc. - Phage Pharmaceuticals, Inc. - PharmaEssentia Corporation - SynBio LLC - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Versartis, Inc. - XL-protein GmbH Drug Profiles: - somatropin SR - MOD-4023 - tesamorelin acetate - MOD-4023 - ARX-201 - ACP-001 - TV-1106 - SYN-20100504RU - somatropin - HL-032 - somatropin - ALRN-5281 - somatropin biobetter - CP-016 - CobOral hGH - BBT-031 - somatropin biosimilar - IBPB-003-HH - somatropin biosimilar - Vaccine For Growth Hormone Deficiencies - xl-020 - CJ-40002 - Pegylated Growth Hormone For more information visit http://www.researchandmarkets.com/research/jd...th_hormone
Versartis Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 05, 8:42AM CDT
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced financial results for the first quarter ended March 31, 2014.
Why Versartis Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 12:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Versartis , a wholly clinical-stage...
Versartis Announces Closing of Its Initial Public Offering and Full Exercise of Over-Allottment Option
GlobeNewswire - Wed Mar 26, 3:05PM CDT
Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company, today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a public offering price of $21 per share, which included 900,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares. The shares began trading on the NASDAQ Global Select Market under the ticker symbol "VSAR" on March 21, 2014. Versartis estimates net proceeds from the offering to be approximately $132.4 million after deducting underwriting discounts and commissions and estimated offering expenses. Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Cowen & Company acted as lead manager and Canaccord Genuity acted as co-manager.
Gilead Sciences Prices Hepatitis C Drug at $84,000; Versartis Commences Trading on the NASDAQ
ACCESSWIRE - Sun Mar 23, 11:30PM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL
Darden, Exelon, Nike are big market movers
AP - Fri Mar 21, 5:59PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
5 IPOs Enjoy Solid Debuts As King Digital Looms
at Investor's Business Daily - Fri Mar 21, 3:32PM CDT
Five IPOs launched Friday, with A10 Networks (ATEN) unexpectedly opening below its pricing while Amber Road (AMBR) and Versatis (VSAR) showed the biggest pop. A10 was the largest of the deals. It priced 12.5 million shares at 15 to raise $187.5...
Versartis (VSAR) Surges on First Trading Day
at The Street - Fri Mar 21, 3:26PM CDT
Biopharmaceutical company Versartis (VSAR) closed up 47.62% to $31 on Friday, its first day of trading after the company's initial public offering. The stock surged more than 50% to a high of $36.30 for the day. Nearly 6 million shares changed hands...
Five companies make their trading debut
AP - Fri Mar 21, 11:12AM CDT
NEW YORK (AP) — Five companies ranging from a drugmaker and a financier to technology providers made their trading debuts Friday led by A10 Networks which brought in the day's top total of $187.5 million through its initial public offering.
NASDAQ Welcomes Versartis, Inc. (NASDAQ:VSAR) to The NASDAQ Stock Market
GlobeNewswire - Fri Mar 21, 11:00AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of Versartis, Inc. (Nasdaq:VSAR), a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, commenced on The NASDAQ Stock Market on March 21, 2014.
Versartis Announces Pricing of Its Initial Public Offering
GlobeNewswire - Thu Mar 20, 8:36PM CDT
Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $21 per share, before underwriting discounts and commissions. The shares are expected to begin trading on the NASDAQ Global Select Market under the ticker symbol "VSAR" on March 21, 2014. In addition, Versartis has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock from Versartis at the initial public offering price. The offering is expected to close on March 26, 2014 subject to customary closing conditions.